Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age70+
SponsorChina National Center for Cardiovascular Diseases
About this trial
To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.
Eligibility criteria
Qualifiers
Age ≥70 years
Patients with atrial fibrillation (atrial fibrillation rhythm of at least 30 seconds duration recorded by ECG or Holter within 1 year)
CHA2DS2-VASc score ≥2 in men and ≥3 in women
Able to cooperate in signing ICFs
Disqualifiers
Moderate-to-severe mitral stenosis, or prior mechanical valve replacement surgery, or unresected atrial myxoma, or known left ventricular thrombus
Prior biological valve replacement or valve repair surgery within 6 months
Left ventricular assist device implantation status
Severe stroke event within 3 months or any stroke within 14 days Major stroke events were defined as those with a Modified Rankin Scale score of 3-5.
Trial design
Treatments tested in this trial
- low-dose rivaroxaban
- Standard-dose rivaroxaban
Treatment groups
4,374 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov